← All trials
NCT04614311
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2020
- Primary completion
- Aug 16, 2023
- Completion date
- Nov 16, 2023
- First posted
- Nov 3, 2020
- Last posted
- Dec 9, 2020
- Enrollment
- 202
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloStudy director
- University of OsloOverall official - principal investigator
- University of OsloReponsible party - principal investigator
- Norwegian University of Science and TechnologyCollaborator
- Government of NorwayCollaborator
- University Hospital of North NorwayCollaborator
- University of BergenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.